Posted in | News | Medical Robotics

Robocath Obtains CE Marking for R-One™, its Robotic-assisted Solution for Treating Coronary Diseases

Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, announces today that it has obtained CE certification for its R-One™ robotic device. As a result, it can begin commercialization in Europe and the Middle East.

R-One™ is the first European robotic solution to obtain the CE mark in the field of interventional cardiology. The robot assists interventional cardiologists in stenting (angioplasty) by enabling precision technologies that complement existing methods, in order to improve procedures and the working environment.

To achieve its objectives, Robocath is planning a new fundraising campaign, with the support of its historical shareholders, for the commercialization of its device over the next few years.

Philippe Bencteux, chairman and founder of Robocath, said: “The whole Robocath team is proud to have taken this major step forward in our development, which comes just a few days after our first sale of a training robot to the Medical Training & Testing Center in Rouen. Our entry into the market for interventional vascular robotics represents a substantial opportunity for growth. There is the potential for the R-One™ solution to be installed in more than 3,000 procedure rooms, performing around 1.6 million interventions each year in Europe alone. Building on our CE mark, we expect to finalize a number of strategic distribution partnerships very shortly in high potential geographic areas, with a Europe and Middle-East wide launch expected in 2020.”

Source: http://www.robocath.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robocath, Inc.. (2019, February 26). Robocath Obtains CE Marking for R-One™, its Robotic-assisted Solution for Treating Coronary Diseases. AZoRobotics. Retrieved on February 24, 2024 from https://www.azorobotics.com/News.aspx?newsID=10321.

  • MLA

    Robocath, Inc.. "Robocath Obtains CE Marking for R-One™, its Robotic-assisted Solution for Treating Coronary Diseases". AZoRobotics. 24 February 2024. <https://www.azorobotics.com/News.aspx?newsID=10321>.

  • Chicago

    Robocath, Inc.. "Robocath Obtains CE Marking for R-One™, its Robotic-assisted Solution for Treating Coronary Diseases". AZoRobotics. https://www.azorobotics.com/News.aspx?newsID=10321. (accessed February 24, 2024).

  • Harvard

    Robocath, Inc.. 2019. Robocath Obtains CE Marking for R-One™, its Robotic-assisted Solution for Treating Coronary Diseases. AZoRobotics, viewed 24 February 2024, https://www.azorobotics.com/News.aspx?newsID=10321.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit
Azthena logo

AZoM.com powered by Azthena AI

Your AI Assistant finding answers from trusted AZoM content

Azthena logo with the word Azthena

Your AI Powered Scientific Assistant

Hi, I'm Azthena, you can trust me to find commercial scientific answers from AZoNetwork.com.

A few things you need to know before we start. Please read and accept to continue.

  • Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
  • Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
  • Large Language Models can make mistakes. Consider checking important information.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.